Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.004500%Not Available
Splenomegaly01.09.02.0010.001780%Not Available
Status epilepticus17.12.03.0050.000392%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stomatitis07.05.06.005--
Stridor22.04.02.0030.002653%
Stupor19.02.05.004; 17.02.04.0070.000224%Not Available
Suffocation feeling22.12.02.0140.000672%Not Available
Supraventricular tachycardia02.03.03.0120.000168%
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.018; 08.01.03.1000.000951%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.002686%Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.0120.001399%
Tachycardia02.03.02.0070.006716%Not Available
Tachypnoea22.02.01.0140.001511%Not Available
Tenderness08.01.08.0050.000168%Not Available
Tension19.06.02.0050.000392%Not Available
Tetany15.05.03.013; 14.04.01.005; 05.04.02.0030.000112%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.002216%Not Available
Throat tightness19.01.02.005; 22.12.03.0310.005932%Not Available
Thrombocytopenia01.08.01.0020.006548%Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000728%Not Available
Tongue disorder07.14.01.0020.000806%Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.001623%Not Available
Torsade de pointes02.03.04.005--Not Available
Toxic encephalopathy12.03.01.027; 17.13.01.0040.000224%Not Available
Tremor17.01.06.0020.007701%
Trigeminal neuralgia17.04.08.001--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene